Nevirapine Amarox

Nevirapine, the active ingredient in Nevirapine Amarox, is a Non-nucleoside reverse transcriptase inhibitor presented as an oral tablet for oral use. It treats HIV-1 infection in adults and children.

GNH USA supplies Nevirapine Amarox as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nevirapine is a non‑nucleoside reverse transcriptase inhibitor used in the management of HIV‑1 infection, typically as part of combination antiretroviral therapy. - HIV‑1 infection (treatment): reduces plasma HIV RNA levels and improves immune function. - Combination antiretroviral therapy (HAART): contributes to overall viral suppression when used with other antiretrovirals. - Treatment‑experienced HIV‑1 infection: provides an option for patients with resistance to other agents.

Nevirapine may cause a range of adverse reactions, from mild to severe. Monitoring for side effects is essential during therapy.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional gastrointestinal discomfort. - Fatigue: feeling of tiredness or weakness. - Headache: transient cranial pain. - Dizziness: light‑headed sensation. - Abdominal pain: mild stomach discomfort.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate discontinuation. - Hepatic failure: signs of liver toxicity such as jaundice. - Severe hypersensitivity: systemic allergic response. - Neutropenia: marked reduction in white blood cells. - Hepatotoxicity: elevated liver enzymes indicating liver injury.

Nevirapine requires careful monitoring due to potential hepatic and dermatologic risks. - Liver function monitoring: assess transaminases before and during treatment. - Pre‑existing hepatic disease: avoid or use with caution in severe liver impairment. - Rash management: discontinue if severe or progressing to Stevens‑Johnson syndrome. - Pregnancy considerations: safety data are limited; evaluate risk‑benefit. - Drug resistance: avoid monotherapy to prevent resistance development. - Store below 25°C: keep in the original pack, protect from moisture.

Nevirapine interacts with several agents that can alter its plasma levels or increase toxicity.

Major Interactions (Avoid): - Rifampin: induces metabolism, reducing nevirapine exposure. - St. John’s wort: strong enzyme inducer, markedly lowers drug levels. - Protease inhibitors (e.g., ritonavir): can increase nevirapine concentrations and risk of hepatotoxicity. - Carbamazepine: induces metabolism, decreasing efficacy.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may raise nevirapine levels. - Macrolide antibiotics (e.g., erythromycin): modest increase in exposure. - Oral contraceptives: nevirapine may reduce hormonal efficacy. - Warfarin: potential alteration of anticoagulant effect, monitor INR.